Clinical prognostic indices in PMF
| Prognostic Index/Reference . | Prognostic factors . | Outcomes . | Notes . |
|---|---|---|---|
| IPSS4 | Age >65 y old Constitutional symptoms Hgb <10 g/dL WBC >25 × 103/µL Circulating blasts >1% | Median OS, mo Low risk: 135 Int-1 risk: 95 Int-2 risk: 48 High risk: 27 | Designed for PMF population Calculated using values at diagnosis |
| DIPSS5 | Age >65 y old Constitutional symptoms Hgb <10 g/dL WBC >25 × 103/µL Circulating blasts >1% | Median OS, y Low risk: not reached Int-1 risk: 14.2 Int-2 risk: 4 High risk: 1.5 | Designed for PMF population Can be recalculated throughout clinical course |
| DIPSS+6 | Age >65 y old Constitutional symptoms Hgb <10 g/dL WBC >25 × 103/µL Circulating blasts >1% Platelet <100 × 103/µL Transfusion dependence Unfavorable karyotype* | Median OS, mo Low risk: 180 Int-1 risk: 80 Int-2 risk: 35 High risk: 16 | Designed for PMF Incorporates additional prognostic factors to DIPSS |
| Prognostic Index/Reference . | Prognostic factors . | Outcomes . | Notes . |
|---|---|---|---|
| IPSS4 | Age >65 y old Constitutional symptoms Hgb <10 g/dL WBC >25 × 103/µL Circulating blasts >1% | Median OS, mo Low risk: 135 Int-1 risk: 95 Int-2 risk: 48 High risk: 27 | Designed for PMF population Calculated using values at diagnosis |
| DIPSS5 | Age >65 y old Constitutional symptoms Hgb <10 g/dL WBC >25 × 103/µL Circulating blasts >1% | Median OS, y Low risk: not reached Int-1 risk: 14.2 Int-2 risk: 4 High risk: 1.5 | Designed for PMF population Can be recalculated throughout clinical course |
| DIPSS+6 | Age >65 y old Constitutional symptoms Hgb <10 g/dL WBC >25 × 103/µL Circulating blasts >1% Platelet <100 × 103/µL Transfusion dependence Unfavorable karyotype* | Median OS, mo Low risk: 180 Int-1 risk: 80 Int-2 risk: 35 High risk: 16 | Designed for PMF Incorporates additional prognostic factors to DIPSS |
Hgb, hemoglobin; Int, intermediate; OS, overall survival.
Unfavorable karyotype: complex karyotype or sole or 2 abnormalities that include 8, 7/7q−, i(17q), 5/5q−, 12p−, inv(3), or 11q23 rearrangement.